Welcome to our dedicated page for Abcellera Biologics news (Ticker: ABCL), a resource for investors and traders seeking the latest updates and insights on Abcellera Biologics stock.
AbCellera Biologics Inc. (Nasdaq: ABCL) is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines in endocrinology, women’s health, immunology, and oncology. The ABCL news feed on Stock Titan aggregates company announcements, clinical updates, financial disclosures, and other material events drawn from AbCellera’s press releases and regulatory filings.
Investors and followers of ABCL can use this page to review news on AbCellera’s internal pipeline, including its lead programs ABCL635 and ABCL575. Recent announcements describe ABCL635 as a potential first-in-class non-hormonal antibody treatment for moderate-to-severe vasomotor symptoms associated with menopause, now in a Phase 1/2 clinical trial, and ABCL575 as an Fc-silenced, half-life extended investigational antibody therapy in a Phase 1 study for moderate-to-severe atopic dermatitis with potential applications in other inflammatory and autoimmune conditions.
The ABCL news stream also captures business and corporate developments, such as quarterly business results, updates on partner-initiated programs and molecules in the clinic, and changes in leadership and board composition. In addition, it includes disclosures on legal and intellectual property matters, including AbCellera’s settlement and patent license agreement with Bruker Corporation that resolved patent litigation globally and provides for upfront and royalty payments.
By reviewing this curated news page, readers can follow how AbCellera advances its antibody discovery and development engine, expands its clinical-stage pipeline, and manages its partnered programs and intellectual property. Bookmark this ABCL news section to quickly access company-issued updates, earnings announcements, clinical trial milestones, and other material information relevant to AbCellera’s operations and strategy.
AbCellera (Nasdaq: ABCL) announced the publication of preclinical data in Science Translational Medicine demonstrating the high potency of bamlanivimab (LY-CoV555) against SARS-CoV-2. The findings indicate that bamlanivimab significantly reduces viral load post-exposure, highlighting its potential to decrease viral shedding and transmission. In clinical trials, bamlanivimab has shown to cut hospitalizations by 70% in high-risk COVID-19 patients. It has also been authorized in over 15 countries and supports ongoing efforts to develop next-generation antibodies.
AbCellera (Nasdaq: ABCL) has announced an expanded collaboration with Gilead Sciences that includes a multi-year, multi-target antibody discovery initiative and access to AbCellera's Trianni Mouse® technology. The agreement entails upfront payments, milestone payments, and royalties based on the commercialization of antibodies developed. AbCellera will produce panels of antibodies for up to eight new targets across various indications, enhancing drug development efficiency with advanced technology.
AbCellera (Nasdaq: ABCL) announced positive results from a Phase 3 trial of bamlanivimab and etesevimab, reducing COVID-19-related hospitalizations and deaths by 87% in high-risk patients. No deaths occurred in the treatment group, while 14 were reported in the placebo cohort. Milestones achieved include Emergency Use Authorization from the FDA and expanded access in the EU. The study involved 769 patients, showing a safety profile consistent with earlier trials. Bamlanivimab was the first COVID-19 therapeutic candidate to receive FDA EUA.
AbCellera (Nasdaq: ABCL) announced a positive scientific opinion from the EMA's CHMP for the use of bamlanivimab alone and in combination with etesevimab for treating COVID-19 in high-risk patients aged 12 and older. This recommendation allows EU member states to make informed decisions on therapy usage before market authorization. The CHMP opinion was backed by positive results from Eli Lilly's BLAZE-1 trial, showing a 70% reduction in hospitalization rates. Bamlanivimab has also received authorization in over 10 countries and generated $871 million in sales in 2020.
AbCellera (NASDAQ: ABCL) will present at the 10th Annual SVB Leerink Global Healthcare Conference on February 25, 2021, at 1:20 p.m. PT. A live audio webcast will be accessible on AbCellera’s Investor Relations website, with a replay available afterward. AbCellera is a technology company focused on discovering antibodies from natural immune systems, partnering with drug developers to accelerate drug development and reduce costs. The press release includes forward-looking statements about potential risks and uncertainties in their business operations.
AbCellera (Nasdaq: ABCL) has appointed Ester Falconer, Ph.D., as Chief Technology Officer effective January 28, 2021. Dr. Falconer will oversee the company's strategy to enhance therapeutic antibody discovery technologies. Previously, she led R&D at AbCellera and contributed significantly to the development of the COVID-19 therapeutic bamlanivimab. Her appointment is expected to strengthen leadership and innovation within the company. Dr. Falconer has been with AbCellera since 2015, advancing through various roles, and holds a Ph.D. in genetics and cell biology.
AbCellera (Nasdaq: ABCL) announced that bamlanivimab (LY-CoV555) 700 mg, developed with Eli Lilly, received Emergency Use Authorization (EUA) from the FDA for treating mild to moderate COVID-19 in high-risk patients. The therapy demonstrated a 70% reduction in hospitalizations in the Phase 3 BLAZE-1 trial, which involved over 1,000 patients. Lilly plans to manufacture over 250,000 doses in Q1 2021. Bamlanivimab, developed from an antibody discovered in a recovered COVID-19 patient, is part of AbCellera's pandemic response efforts, identifying over 2,300 unique antibodies.
AbCellera (Nasdaq: ABCL) is set to announce its fourth-quarter and full-year 2020 financial results on March 29, 2021, after U.S. market close. An earnings conference call will follow at 2:00 p.m. PT (5:00 p.m. ET). The live webcast will be accessible via AbCellera’s Investor Relations website, with a replay available post-call.
AbCellera specializes in discovering and analyzing antibodies for drug development, collaborating with various drug developers to streamline processes and reduce costs.
AbCellera (Nasdaq: ABCL) announced that its antibody, bamlanivimab, will be evaluated alongside VIR-7831 as a potential COVID-19 therapy for low-risk patients with mild to moderate illness. Bamlanivimab has been shown to reduce the risk of COVID-19 by up to 80%, prevent deaths, and decrease hospitalizations by 70%-80%. Currently authorized in multiple countries, bamlanivimab was developed in partnership with Eli Lilly and has been administered to over 100,000 patients since receiving Emergency Use Authorization from the FDA in November 2020.
AbCellera (Nasdaq: ABCL) has announced compelling results from the BLAZE-1 Phase 2/3 study, where bamlanivimab and etesevimab significantly reduced COVID-19-related hospitalizations and deaths by 70% compared to placebo. In a trial involving over 1,000 high-risk patients, all deaths occurred in the placebo group. Bamlanivimab was the first monoclonal antibody authorized by the FDA for COVID-19 treatment. AbCellera continues to enhance its pandemic response capabilities, having identified over 2,300 unique anti-SARS-CoV-2 antibodies.